Precision Medicine in Neurodegenerative Diseases: Genomic Approaches to Target Amyloid-β, Tau, and Alpha-Synuclein Pathways

Precision medicine for sodium channelopathy-related autism and epilepsy.

Recent advances in omics technologies have led to unprecedented efforts characterizing the molecular changes that underlie the development and progression of a wide array of complex human diseases, including cancer. As a result, multi-omics analyses—which take advantage of these technologies in genomics, transcriptomics, epigenomics, proteomics, metabolomics, and other omics areas—have been proposed and heralded as the key to advancing precision medicine in the clinic. In the field of precision oncology, genomics approaches, and, more recently, other omics analyses have helped reveal several key mechanisms in cancer development, treatment resistance, and recurrence risk, and several of these findings have been implemented in clinical oncology to help guide treatment decisions. However, truly integrated multi-omics analyses have not been applied widely, preventing further advances in precision medicine. Additional efforts are needed to develop the analytical infrastructure necessary to generate, analyze, and annotate multi-omics data effectively to inform precision medicine-based decision-making.

Artificial Intelligence (AI) is revolutionizing healthcare by augmenting diagnostic accuracy, personalizing treatment plans, and accelerating drug discovery processes. This review synthesizes current literature and case studies to explore AI's multifaceted applications in healthcare. The review begins by examining AI's role in early disease detection, highlighting its use of advanced techniques such as deep learning and neural networks for analyzing medical images with unprecedented precision. Case studies underscore AI's success in detecting cancers and predicting cardiovascular risks, demonstrating significant advancements in diagnostic capabilities. Moving to personalized treatment, the review explores how AI integrates genomic data, electronic health records (EHRs), and lifestyle information to tailor medical interventions. AI-driven predictive analytics enable the forecasting of treatment outcomes and the recommendation of optimal personalized therapies, enhancing patient care and treatment efficacy. In the realm of drug discovery and development, AI algorithms expedite the identification of potential drug targets, optimize molecular designs, and predict clinical trial outcomes. Case examples illustrate AI's effectiveness in discovering novel compounds and repurposing existing drugs, promising accelerated innovation in pharmaceutical research. Ethical considerations, including data privacy and algorithmic bias, are critically analyzed alongside regulatory frameworks like GDPR and FDA guidelines, ensuring responsible AI implementation in healthcare. Ultimately, this review underscores AI's transformative impact on healthcare delivery, offering insights into its potential to reshape medical practices, improve patient outcomes, and pave the way for future advancements in precision medicine and therapeutic innovation.

Clustered regularly interspaced short palindromic repeats (CRISPR) genome editing platform heralds a new era of gene therapy. Innovative treatments for life-threatening monogenic diseases of the blood and immune system are transitioning from semi-random gene addition to precise modification of defective genes. As these therapies enter first-in-human clinical trials, their long-term safety and efficacy will inform the future generation of genome editing-based medicine. Here we discuss the significance of Inborn Errors of Immunity as disease prototypes for establishing and advancing precision medicine. We will review the feasibility of clustered regularly interspaced short palindromic repeats-based genome editing platforms to modify the DNA sequence of primary cells and describe two emerging genome editing approaches to treat RAG2 deficiency, a primary immunodeficiency, and FOXP3 deficiency, a primary immune regulatory disorder.

Genome and transcriptome engineering have emerged as powerful tools in modern biotechnology, driving advancements in precision medicine and novel therapeutics. In this review, we provide a comprehensive overview of the current methodologies, applications, and future directions in genome and transcriptome engineering. Through this, we aim to provide a guide for tool selection, critically analyzing the strengths, weaknesses, and best use cases of these tools to provide context on their suitability for various applications. We explore standard and recent developments in genome engineering, such as base editors and prime editing, and provide insight into tool selection for change of function (knockout, deletion, insertion, substitution) and change of expression (repression, activation) contexts. Advancements in transcriptome engineering are also explored, focusing on established technologies like antisense oligonucleotides (ASOs) and RNA interference (RNAi), as well as recent developments such as CRISPR-Cas13 and adenosine deaminases acting on RNA (ADAR). This review offers a comparison of different approaches to achieve similar biological goals, and consideration of high-throughput applications that enable the probing of a variety of targets. This review elucidates the transformative impact of genome and transcriptome engineering on biological research and clinical applications that will pave the way for future innovations in the field.

The advancement of precision medicine in medical care has led behind the conventional symptom-driven treatment process by allowing early risk prediction of disease through improved diagnostics and customization of more effective treatments. It is necessary to scrutinize overall patient data alongside broad factors to observe and differentiate between ill and relatively healthy people to take the most appropriate path toward precision medicine, resulting in an improved vision of biological indicators that can signal health changes. Precision and genomic medicine combined with artificial intelligence have the potential to improve patient healthcare. Patients with less common therapeutic responses or unique healthcare demands are using genomic medicine technologies. AI provides insights through advanced computation and inference, enabling the system to reason and learn while enhancing physician decision making. Many cell characteristics, including gene up-regulation, proteins binding to nucleic acids, and splicing, can be measured at high throughput and used as training objectives for predictive models. Researchers can create a new era of effective genomic medicine with the improved availability of a broad range of datasets and modern computer techniques such as machine learning. This review article has elucidated the contributions of ML algorithms in precision and genome medicine.

Objective Inflammatory Bowel Disease (IBD) poses a persistent challenge in the realm of gastroenterology, necessitating continual exploration of innovative treatment strategies. The limited efficacy and potential side effects associated with existing therapeutic modalities underscore the urgent need for novel approaches in IBD management. This study aims to examine potential therapeutic targets and recent advancements in understanding the disease’s intricate pathogenesis, with a spotlight on the gut microbiome, immune dysregulation, and genetic predispositions. Methods A comprehensive review was conducted to delve into the pressing demand for new avenues in IBD treatment. The study examined potential therapeutic targets such as phosphodiesterase 4 (PDE4) inhibitors, immune system modulators, Tyrosine kinase receptors (TYK), Toll-like receptors (TLRs), modulation of the gut microbiota, stem cell therapy, fibrosis management, interleukins (ILs) regulation, and oxidative stress mitigation. Additionally, advances in precision medicine, biologics, small molecule inhibitors, and microbiome modulation techniques were explored. Results The investigation unveiled promising therapeutic targets and provided insights into recent breakthroughs that herald a transformative era in the therapeutic landscape for IBD. Advances in precision medicine, biologics, small molecule inhibitors, and the exploration of microbiome modulation techniques stood out as pivotal milestones in the field of gastroenterology. Conclusions The findings offer renewed hope for enhanced efficacy, reduced side effects, and improved patient outcomes in the treatment of IBD. These innovative approaches necessitate continual exploration and underscore the urgent need for novel strategies in IBD management, potentially revolutionizing the realm of gastroenterology.

Abstract: Precision medicine has emerged as a promising approach for personalized healthcare, particularly in the field of cardiovascular diseases (CVDs). Diagnostic approach in early basis plays a crucial impact in improving patient outcomes, as it permits timely intervention and tailored treatment strategies. Nanosensors, with their unique properties and capabilities, offer groundbreaking opportunities for detection in the primary phase and as well as disease monitoring. The basic fundamental principles of Nanosensors are important to understand the mechanism of working and utilization of the technique. Cardiac diseases are the foremost origin of illness and mortality all over the globe. The physical, biological and pathophysiology of CVDs can be precisely identified by appropriate and exact detection of pertinent biomarkers and function limits. Nanosensors basically incorporate the benefit of Nanomaterials for detection methods. Nanosensors generally exposed a great possible approach for speedy detection of CVDs, specifically in primary prophecy. Advancement of current therapy in Nanosensors for recognition of cardiac disease are briefed, including different types of sensors such as optical, electrochemical, paper-based and pressure Nanosensors. Though Nanoparticles raise the impact on health, there are some limitations in scalability, and standardization of the Nanosensor having good selectivity, efficacy, sensitivity, biocompatibility and limit of detection as compared to the conventional way. Project tactics for various Nanosensors via conforming identifying Nanomaterials, with their mechanistic approach, highlight the potential of precision medicine as well as Nanosensor.

Head and neck cancer (HNC) represents a heterogeneous group of malignancies arising from various sites within the upper aerodigestive tract and posing significant challenges in diagnosis, treatment, and management. Precision medicine has emerged as a promising approach to address these challenges by tailoring treatment strategies to the molecular and genetic characteristics of individual tumors. It holds tremendous promise in revolutionizing HNC management by offering personalized treatment approaches that improve patient outcomes and quality of life. Technological advancements in precision medicine have attracted much attention and challenged scientists. However, challenges such as tumor heterogeneity, treatment resistance, and access to molecular profiling in the management of HNC remain to be addressed. In this context, precision medicine is revolutionizing the approach of personalizing HNC treatment by tailoring therapeutic approaches based on individual patients’ “omics” profiles. This chapter focuses on the paradigm shift brought about by precision medicine in the realm of HNC treatment.

Genome editing has revolutionized modern biotechnology, enabling precise modifications to DNA sequences with far-reaching applications in medicine, agriculture, and synthetic biology. Recent advancements in artificial intelligence (AI) have significantly enhanced genome editing by improving target selection, minimizing off-target effects, and optimizing CRISPR-associated systems. AI-driven models, such as deep learning-based predictors and protein language models, enable more accurate sgRNA design, novel Cas protein discovery, and enhanced gene regulatory network analysis. Additionally, AI-powered tools facilitate large-scale data integration, accelerating functional genomics and therapeutic genome editing. This review explores the intersection of AI and genome editing, highlighting key innovations, challenges, and future prospects. Despite its transformative potential, AI-driven genome editing raises ethical concerns regarding data bias, algorithmic transparency, and unintended genetic modifications. Addressing these challenges requires interdisciplinary collaboration between AI researchers, molecular biologists, and policymakers. As AI continues to evolve, its integration with genome editing will pave the way for groundbreaking advancements in precision medicine, genetic disease treatment, and sustainable agriculture.

In recent years, the concept of precision medicine—an approach to developing personalized drugs for disease prevention or treatment—has emerged as an up-and-coming field in medical research. However, there are numerous limitations to applying this approach to the treatment of neurodegenerative diseases, such as Alzheimer disease, because of the invasiveness of obtaining human brain samples. Meanwhile, the development of human brain organoids has become one of the most powerful in vitro research tools because these organoids can be established from induced pluripotent stem cells or embryonic stem cells. In this review, we discuss how we can effectively utilize brain organoids for precision medicine research in conjunction with a variety of high-end techniques such as clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR-Cas9) genomic editing, integrative multi-omics analysis, 3D brain tissue clearing, and high-content screening confocal microscopy imaging systems. We herein provide new insights in order to materialize organoid-based precision medicine therapy and future directions.

Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence

Rapid advances in precision medicine promise dramatic reductions in morbidity and mortality for a growing array of conditions. To realize the benefits of precision medicine and minimize harm, it is necessary to address real-world challenges encountered in translating this research into practice. Foremost among these is how to choose and use precision medicine modalities in real-world practice by addressing issues related to caring for the sizable proportion of people living with multimorbidity. Precision medicine needs to be delivered in the broader context of precision care to account for factors that influence outcomes for specific therapeutics. Precision care integrates a person-centered approach with precision medicine to inform decision making and care planning by taking multimorbidity, functional status, values, goals, preferences, social and societal context into account. Designing dissemination and implementation of precision medicine around precision care would improve person-centered quality and outcomes of care, target interventions to those most likely to benefit thereby improving access to new therapeutics, minimize the risk of withdrawal from the market from unanticipated harms of therapy, and advance health equity by tailoring interventions and care to meet the needs of diverse individuals and populations. Precision medicine delivered in the context of precision care would foster respectful care aligned with preferences, values, and goals, engendering trust, and providing needed information to make informed decisions. Accelerating adoption requires attention to the full continuum of translational research: developing new approaches, demonstrating their usefulness, disseminating and implementing findings, while engaging patients throughout the process. This encompasses basic science, preclinical and clinical research and implementation into practice, ultimately improving health. This article examines challenges to the adoption of precision medicine in the context of multimorbidity. Although the potential of precision medicine is enormous, proactive efforts are needed to avoid unintended consequences and foster its equitable and effective adoption.

Rapid advances in precision medicine promise dramatic reductions in morbidity and mortality for a growing array of conditions. To realize the benefits of precision medicine and minimize harm, it is necessary to address real-world challenges encountered in translating this research into practice. Foremost among these is how to choose and use precision medicine modalities in real-world practice by addressing issues related to caring for the sizable proportion of people living with multimorbidity. Precision medicine needs to be delivered in the broader context of precision care to account for factors that influence outcomes for specific therapeutics. Precision care integrates a person-centered approach with precision medicine to inform decision making and care planning by taking multimorbidity, functional status, values, goals, preferences, social and societal context into account. Designing dissemination and implementation of precision medicine around precision care would improve person-centered quality and outcomes of care, target interventions to those most likely to benefit thereby improving access to new therapeutics, minimize the risk of withdrawal from the market from unanticipated harms of therapy, and advance health equity by tailoring interventions and care to meet the needs of diverse individuals and populations. Precision medicine delivered in the context of precision care would foster respectful care aligned with preferences, values, and goals, engendering trust, and providing needed information to make informed decisions. Accelerating adoption requires attention to the full continuum of translational research: developing new approaches, demonstrating their usefulness, disseminating and implementing findings, while engaging patients throughout the process. This encompasses basic science, preclinical and clinical research and implementation into practice, ultimately improving health. This article examines challenges to the adoption of precision medicine in the context of multimorbidity. Although the potential of precision medicine is enormous, proactive efforts are needed to avoid unintended consequences and foster its equitable and effective adoption.

Rapid advances in precision medicine promise dramatic reductions in morbidity and mortality for a growing array of conditions. To realize the benefits of precision medicine and minimize harm, it is necessary to address real-world challenges encountered in translating this research into practice. Foremost among these is how to choose and use precision medicine modalities in real-world practice by addressing issues related to caring for the sizable proportion of people living with multimorbidity. Precision medicine needs to be delivered in the broader context of precision care to account for factors that influence outcomes for specific therapeutics. Precision care integrates a person-centered approach with precision medicine to inform decision making and care planning by taking multimorbidity, functional status, values, goals, preferences, social and societal context into account. Designing dissemination and implementation of precision medicine around precision care would improve person-centered quality and outcomes of care, target interventions to those most likely to benefit thereby improving access to new therapeutics, minimize the risk of withdrawal from the market from unanticipated harms of therapy, and advance health equity by tailoring interventions and care to meet the needs of diverse individuals and populations. Precision medicine delivered in the context of precision care would foster respectful care aligned with preferences, values, and goals, engendering trust, and providing needed information to make informed decisions. Accelerating adoption requires attention to the full continuum of translational research: developing new approaches, demonstrating their usefulness, disseminating and implementing findings, while engaging patients throughout the process. This encompasses basic science, preclinical and clinical research and implementation into practice, ultimately improving health. This article examines challenges to the adoption of precision medicine in the context of multimorbidity. Although the potential of precision medicine is enormous, proactive efforts are needed to avoid unintended consequences and foster its equitable and effective adoption.